Copy URL
The finished product agreement allows Solution Biologics to purchase and CanSino to supply the finished vaccine for emergency use in Malaysia. – AFP pic, July 30, 2021.
SOLUTION Group Bhd’s (SGB) wholly owned subsidiary, Solution Biologics Sdn Bhd (Solbio) has signed a finished product and a bulk product agreement today with CanSino Biologics Inc for the supply of the Recombinant Ad5-nCoV vaccine against Covid-19.
In a statement, the group said the finished product agreement allows Solbio to purchase and CanSino to supply the finished vaccine for emergency use in Malaysia.
Effective July 2018, access to full reports will only be available with a subscription. Sign-up now and enjoy one (1) week free access!